1 / 24

Vogt-Koyanagi-Harada Syndrome

Vogt-Koyanagi-Harada Syndrome. Laura S. Gilmore, MD Department of Ophthalmology November 12, 2004 Discussant: Leo Dominguez, MD. Case Presentation. CC : loss of vision and hearing

harva
Télécharger la présentation

Vogt-Koyanagi-Harada Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vogt-Koyanagi-Harada Syndrome Laura S. Gilmore, MD Department of Ophthalmology November 12, 2004 Discussant: Leo Dominguez, MD

  2. Case Presentation • CC: loss of vision and hearing • HPI: 38 yo HF with3 wk h/o progressively decreasing vision OD, irregular pupils. Seen by multiple MDs. Treated at onset for “allergies”, then by Ophtho in NM with PO prednisone at 80mg/day, PF and Atropine for about 1 week prior to presentation here. • PMH: No arthritis, RA, lupus, DM, HTN. +HepC. • POH: Poor vision OS since 10yo 2o trauma. No h/o glasses’ wear. • ROS: +Tinnitus, hearing loss, ocular pain, photophobia, scalp and hair tenderness, L occipital HA, poor balance/vertigo, hair/lash/brow thinning, hypopigmentation of face/arms, back pain.

  3. Physical Exam • General: AAO, BP 110/61, pulse 53. Poor hearing, poor balance. • VA: 20/150 OD, LP OS • Pupils: 5 NR OU, irregularly shaped • External: Thin brows, lashes OU; splotchy white patches of skin over face, forehead, arms • SLE: KP OU; posterior synechiae OU; 4+C/F; 3+pigment on anterior capsule; 4+ vitreous cells • Lens: 2+NSC/2+PSC OU • B Scan: Serous RD OU; choroidal thickening; + vitreous cells

  4. Differential Diagnosis • VKH • Posterior scleritis • Uveal effusion syndrome • Harada's disease • Acute posterior multifocal placoid pigment epitheliopathy • Sympathetic ophthalmia • Sarcoidosis

  5. VKH • Uveoencephalitis • Extremely rare systemic disease of melanocyte-containing organs • Characterized by bilateral uveitis with associated cutaneous, neurologic, and auditory abnormalities • First described by Vogt in 1906 and Koyanagi in 1929 as anterior uveitis with poliosis, vitiligo, auditory disturbances (Vogt-Koyanagi syndrome) • Harada reported a pt in 1926 with idiopathic uveitis affecting posterior segment, RD, and meningeal irritation • Currently, VKH considered a single entity composed of variations of above symptoms

  6. Etiology • Autoimmune response - Reaction against antigen (tyrosinase or tyr-related protein?) shared by uveal, dermal, and meningeal melanocytes - Circulating Ab against a retinal photoreceptor region - HLA-DR4 often present-commonly associated with other autoimmune diseases • Viral reactivation, possibly EBV • Immunogenic predisposition • Almost all cases are sporadic, with only rare familial cases • But, susceptibility associated with specific HLA groups, particularly DRB*0405

  7. Demographics • Rare • No good data on frequency in US • Internationally, widely distributed • Darker pigmented pts • Range of presentation 10-52 years, maximum frequency in thirties • Women affected more

  8. Clinical Presentation, Phase One • Prodromal (or meningeal) • Few days • HA, fever, photophobia, meningismus • Less common: gen muscle weakness, hemiparesis, dysarthria, aphasia • Altered mental status, from mild confusion to psychosis

  9. Clinical Presentation, Phase Two • Uveitic • Several weeks • When pt’s typically seek medical attention, usually from Ophthalmologist • Bilateral blurred vision • Eye pain and irritation • Loss of vision • Tinnitus and dysacusis in 50%. May occur in any of the 3 phases of VKH

  10. Clinical Presentation • Convalescent phase • Within 3 months of syndrome onset • Cutaneous signs • Usually after onset of uveitis • Have been reported years before any ocular sx • Patchy alopecia • Poliosis (in 90%) involving eyebrows, eyelashes, body hair and scalp • Symmetrical vitiligo (in 63%) over head and trunk

  11. Diagnosis • American Uveitis Society guidelines • No ocular trauma or surgery • At least 3 of following 4: • B chronic inflammation of iris and CB • Posterior uveitis, including multifocal exudative RDs, and disc hyperemia or edema • Neurological signs of tinnitus, neck stiffness, CN or CNS dysfunction, cerebrospinal pleocytosis • Cutaneous findings of alopecia, poliosis, or vitiligo • A-scan and B-scan • Multidisciplinary management • Consider LP for CSF analysis, FA, audiometry, skin biopsy.

  12. Treatment • Goal-reduce morbidity and prevent complications • Suppress initial intraocular inflammation • Early and aggressive systemic steroids • 60-100mg PO QD • Slow taper over 3-6 months • Unresponsive pts • Immunosuppression with azathioprine, cyclophosphamide, or methotrexate • Topical therapy • Steroid gtts • Cycloplegic-mydriatic gtts for sx relief

  13. Prognosis • No mortality • Visual outcome depends on rapidity and appropriateness of tx • Uncommon to have long term complications • Reversible and irreversible vision loss • IOP elevation • Glaucoma • Cataracts • Hearing almost always completely resolves • Cutaneous pigmentary changes usually permanent

  14. Back to Our Case • Hospital Admission 7/11/03 • IM, Rheumatology, Audiology, Gynecology • Labs: • daily CBC and BMP, ESR, toxoplasma, ACE, FTA-ABS, RPR, ANA, PPD, Lyme titer, lupus anticoagulant, anticardiolipin Ab, anti-dsDNA, SSA Ab, SSB Ab, HLA-B27, hepatitis panel, HIV, VDRL, antiproteinase III, UA, antimyeloperoxidase, beta-HCG, AP/lateral CXR and LXR, CT head/orbits, MRI head/orbits • Meds: • Solumedrol IV 1g/day per Rheum; PF gtt; atropine; pepcid; azathioprine 100mg/day; tacrolimus, 2.5mg PO BID

  15. Results • MRI: • no inflammatory process in brain or surrounding structures • Labs: • ANA weakly positive, HepC +; all else normal or negative, X-rays nl • Audiology: • mild sensorineural hearing loss

  16. Hospital Course • Improved hearing, balance, and visual acuity throughout hospital stay -VA 20/70 OD, LP OS -no cells/1+flare OU -decreased KP, vitreous cells -DFE: improved view OU; inferior SRD OD, almost 360o SRD OS • Discharged home at 1 week on PO Prednisone, Tacrolimus, Azathioprine, PF gtt, Atropine, Maxitrol ung

  17. Relevant Clinical Course Since Discharge • 7/18/03-Discharged home, s/p 1 week IV steroid therapy, aggressive immunosuppression • 8/03-Timolol and Trusopt required for IOP 31, 34 • 10/17/03- 20/40 OD, CF @ 2ft OS, inflammation cleared, retina completely attached OU • 11/03-began tapering Prograff, Azathioprine (Rheumatology) • 12/03-began tapering PO prednisone and PF, d/c’d atropine

  18. Clinical Course, Continued • 7/04-3-4+Uveitic PSC OU • 10/6/04-CE/PCIOL OD • 10/14/04-VA 20/30, very happy (with us) • Immunosuppression low-dose now • Currently on prednisone 20mg PO QD, azathioprine 50mg PO TID • Still requiring timolol and trusopt gtt

  19. Conclusion • Very rare • Multidisciplinary treatment approach • Early and aggressive immunosuppression with slow, prolonged taper required to improve outcome and decrease long-term complications • Often have good outcomes

  20. References • Choczaj-Kukula A, et al. Vogt-Koyanagi-Harada Syndrome: eMedicine.com. Sept 2003. • Fattal D. Vogt-Koyanagi-Harada Syndrome (VKH): summary and discussion of case presentation. Dept of Neurology, Baylor College of Medicine. 2001: www.bcm.tmc.edu/neuro1/index.html • Islam SM, et al. HLA class genes in VKH disease. Invest Ophthalmol Vis Sci. 1994. 35: 3890-3896. • Nussenblatt, RB, et al. Uveitis, Fundamentals and Clinical Practice. 1996. 312-324. • Snyder DA, et al. VKH syndrome. Am J Ophthalmol. 1980. 90: 69-75.

More Related